Literature DB >> 20407977

Pharmacotherapy in the treatment of addiction: methadone.

Mary Jeanne Kreek1, Lisa Borg, Elizabeth Ducat, Brenda Ray.   

Abstract

Methadone maintenance treatment (MMT) is the most widely available pharmacotherapy for opioid addiction and has been shown to be an effective and safe treatment over a period of 40 years. Although women comprise approximately 40% of clients currently being treated in MMT programs, comparatively little research geared specifically toward this group has been published. This article begins with an overview of neurobiological studies on opioid addiction, including a discussion of gender differences, followed by a review of the pharmacology of methadone. The authors then examine the particular needs and differences of women being treated in MMTs, including co-dependence with other substances, women's health issues, and psychosocial needs unique to this population. Research shows that women have different substance abuse treatment needs in comparison to their male counterparts. One New York City MMT program that has attempted to address these differences is highlighted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407977      PMCID: PMC2885886          DOI: 10.1080/10550881003684798

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  124 in total

1.  Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients.

Authors:  D M Novick; M J Kreek; P A Arns; L L Lau; S R Yancovitz; A M Gelb
Journal:  Alcohol Clin Exp Res       Date:  1985 Jul-Aug       Impact factor: 3.455

2.  Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment.

Authors:  Steven I Berk; Alain H Litwin; Julia H Arnsten; Evelyn Du; Irene Soloway; Marc N Gourevitch
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

3.  Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: quantitation by direct probe chemical ionization mass spectrometry.

Authors:  M J Kreek; F A Bencsath; F H Field
Journal:  Biomed Mass Spectrom       Date:  1980-09

4.  The pharmacokinetics of heroin in patients with chronic pain.

Authors:  C E Inturrisi; M B Max; K M Foley; M Schultz; S U Shin; R W Houde
Journal:  N Engl J Med       Date:  1984-05-10       Impact factor: 91.245

5.  Methadone disposition in patients with chronic liver disease.

Authors:  D M Novick; M J Kreek; A M Fanizza; S R Yancovitz; A M Gelb; R J Stenger
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

6.  Methadone-disulfiram interaction during methadone maintenance.

Authors:  T G Tong; N L Benowitz; M J Kreek
Journal:  J Clin Pharmacol       Date:  1980 Aug-Sep       Impact factor: 3.126

7.  Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.

Authors:  M I Nilsson; E Anggård; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Altered methadone pharmacokinetics in methadone-maintained pregnant women.

Authors:  S M Pond; M J Kreek; T G Tong; J Raghunath; N L Benowitz
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

9.  Patterns of illicit drug use and retention in a methadone program: a longitudinal study.

Authors:  Ingrid Davstad; Marlene Stenbacka; Anders Leifman; Olof Beck; Seher Korkmaz; Anders Romelsjö
Journal:  J Opioid Manag       Date:  2007 Jan-Feb

10.  Phenytoin-induced methadone withdrawal.

Authors:  T G Tong; S M Pond; M J Kreek; N F Jaffery; N L Benowitz
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  41 in total

1.  A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification.

Authors:  Gregory S Brigham; Natasha Slesnick; Theresa M Winhusen; Daniel F Lewis; Xiamei Guo; Eugene Somoza
Journal:  Drug Alcohol Depend       Date:  2014-02-23       Impact factor: 4.492

Review 2.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

3.  Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Xu Shu; Jurg Ott; Pei-Hong Shen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

Review 4.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

Review 5.  Vaccines against drug abuse.

Authors:  X Y Shen; F M Orson; T R Kosten
Journal:  Clin Pharmacol Ther       Date:  2011-11-30       Impact factor: 6.875

6.  Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Matthew E Layton; Ekaterina Burduli; John M Roll; Walter Ling
Journal:  Am J Drug Alcohol Abuse       Date:  2018-04-19       Impact factor: 3.829

Review 7.  Methadone for neuropathic pain in adults.

Authors:  Ewan D McNicol; McKenzie C Ferguson; Roman Schumann
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  Divergent behavioral responses in protracted opioid withdrawal in male and female C57BL/6J mice.

Authors:  Isabel M Bravo; Brennon R Luster; Meghan E Flanigan; Patric J Perez; Elizabeth S Cogan; Karl T Schmidt; Zoe A McElligott
Journal:  Eur J Neurosci       Date:  2019-10-06       Impact factor: 3.386

Review 10.  Can you vaccinate against substance abuse?

Authors:  Thomas R Kosten; Coreen B Domingo
Journal:  Expert Opin Biol Ther       Date:  2013-04-18       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.